NO20063853L - Kombinasjonsterapi for osteoporose - Google Patents

Kombinasjonsterapi for osteoporose

Info

Publication number
NO20063853L
NO20063853L NO20063853A NO20063853A NO20063853L NO 20063853 L NO20063853 L NO 20063853L NO 20063853 A NO20063853 A NO 20063853A NO 20063853 A NO20063853 A NO 20063853A NO 20063853 L NO20063853 L NO 20063853L
Authority
NO
Norway
Prior art keywords
osteoporosis
combination therapy
antagonists
preparations
agonistsz
Prior art date
Application number
NO20063853A
Other languages
English (en)
Inventor
Hua Zhu Ke
David Thompson
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Publication of NO20063853L publication Critical patent/NO20063853L/no
Application filed by Pfizer filed Critical Pfizer

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Farmasøytiske kombinasjonspreparater som inneholder visse østrogen-agonister/antagonister og prostaglandiner eller prostaglandinagonisterZ-antagonister. Preparatene kan brukes for behandlingen av benhdelser inklusiv osteoporose.
NO20063853A 1996-02-28 2006-08-29 Kombinasjonsterapi for osteoporose NO20063853L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1241296P 1996-02-28 1996-02-28
PCT/IB1996/001462 WO1997031640A1 (en) 1996-02-28 1996-12-23 Combination therapy for osteoporosis

Publications (1)

Publication Number Publication Date
NO20063853L true NO20063853L (no) 1998-08-27

Family

ID=21754846

Family Applications (2)

Application Number Title Priority Date Filing Date
NO19983936A NO323648B1 (no) 1996-02-28 1998-08-27 Farmasoytisk preparat inneholdende en ostrogenagonist/-antagonist og et prostaglandin eller en prostaglandinagonist/-antagonist, anvendelse av disse for fremstilling av et farmasoytisk preparat for behandling av en tilstand karakterisert ved lav benmasse og sett inneholdende samme.
NO20063853A NO20063853L (no) 1996-02-28 2006-08-29 Kombinasjonsterapi for osteoporose

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO19983936A NO323648B1 (no) 1996-02-28 1998-08-27 Farmasoytisk preparat inneholdende en ostrogenagonist/-antagonist og et prostaglandin eller en prostaglandinagonist/-antagonist, anvendelse av disse for fremstilling av et farmasoytisk preparat for behandling av en tilstand karakterisert ved lav benmasse og sett inneholdende samme.

Country Status (45)

Country Link
US (2) US6323232B1 (no)
EP (3) EP1236475A3 (no)
JP (2) JPH11504352A (no)
KR (1) KR19990087337A (no)
CN (5) CN1515316A (no)
AP (3) AP975A (no)
AR (2) AR005987A1 (no)
AT (1) ATE405273T1 (no)
AU (1) AU703285B2 (no)
BG (1) BG64582B1 (no)
BR (1) BR9612533A (no)
CA (1) CA2247420C (no)
CL (1) CL2004000119A1 (no)
CO (1) CO4761063A1 (no)
CZ (1) CZ297452B6 (no)
DE (1) DE69637651D1 (no)
DK (1) DK0883404T3 (no)
DZ (1) DZ2186A1 (no)
ES (1) ES2312169T3 (no)
GT (2) GT199700009A (no)
HK (1) HK1018210A1 (no)
HN (1) HN1996000101A (no)
HR (1) HRP970118A2 (no)
HU (1) HUP9904123A3 (no)
ID (1) ID19886A (no)
IL (3) IL125493A0 (no)
IS (1) IS4812A (no)
MA (1) MA26420A1 (no)
NO (2) NO323648B1 (no)
NZ (1) NZ323456A (no)
OA (1) OA10837A (no)
PE (2) PE58998A1 (no)
PL (2) PL187219B1 (no)
PT (1) PT883404E (no)
RU (1) RU2190395C2 (no)
SI (1) SI0883404T1 (no)
SK (1) SK118398A3 (no)
TN (1) TNSN97040A1 (no)
TR (1) TR199801679T2 (no)
TW (1) TW464496B (no)
UA (1) UA69372C2 (no)
UY (1) UY24472A1 (no)
WO (1) WO1997031640A1 (no)
YU (1) YU7797A (no)
ZA (1) ZA971719B (no)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
AR008155A1 (es) * 1996-09-06 1999-12-09 Smithkline Beecham Corp Uso de un compuesto de formula i para preparar un medicamento util para tratar y prevenir la enfermedad cardiovascular post menopausica en mujeres.
GB2324726A (en) * 1997-05-01 1998-11-04 Merck & Co Inc Combination Therapy for the Treatment of Osteoporosis
SE9702401D0 (sv) 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
AU7349298A (en) 1997-06-23 1999-01-04 Pfizer Inc. Prostaglandin agonists
ID24759A (id) * 1997-09-09 2000-08-03 Procter & Gamble Metoda untuk meningkatkan volume tulang
UA67754C2 (uk) * 1997-10-10 2004-07-15 Пфайзер, Інк. Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)
EP0950417A3 (en) 1998-02-23 2000-02-23 Pfizer Products Inc. Treatment of skeletal disorders
DE69923448T2 (de) * 1998-06-03 2005-12-29 Pfizer Products Inc., Groton 2-aminopyridine mit kondensierten ringsubstituenten als stickstoff-oxid-synthase inhibitoren
AU3342099A (en) * 1998-06-16 2000-01-05 Pfizer Products Inc. Therapeutic combinations of (selective) estrogen receptor modulators (serm) and growth hormone secretagogues (ghs) for treating musculoskeletal frailty
ZA993975B (en) * 1998-06-16 2000-12-15 Pfizer Prod Inc Combination therapy for musculoskeletal frailty.
PA8471201A1 (es) * 1998-06-16 2000-09-29 Pfizer Prod Inc Combinaciones terapeuticas que comprenden un modulador del receptor de estrogenos selectivo y hormona paratiroidea
EP0966968B1 (en) 1998-06-16 2004-05-06 Pfizer Products Inc. Therapeutic combinations comprising a selective estrogen receptor modulator and prostaglandin E2
EP1004306A3 (en) * 1998-08-06 2000-06-07 Pfizer Products Inc. Estrogen agonists/antagonists
US6414006B1 (en) 1998-10-15 2002-07-02 Merck Frosst Canada & Co. Methods for inhibiting bone resorption
TR200200435T2 (tr) * 1998-11-03 2002-07-22 Pfizer Products Inc. Yeni makrolit antibiyotikler.
CA2365326A1 (en) * 1999-03-05 2000-09-08 The Procter & Gamble Company Methods of increasing bone volume using non-naturally-occurring fp selective agonists and antiresorptive compounds
GB9913649D0 (en) * 1999-06-11 1999-08-11 Karobio Ab Estrogen receptor
EP1113007A1 (en) * 1999-12-24 2001-07-04 Pfizer Inc. Tetrahydroisoquinoline compounds as estrogen agonists/antagonists
CO5251465A1 (es) 2000-01-26 2003-02-28 Pfizer Prod Inc Composiciones y procedimientos para tratar la osteoporosis y reducir el colesterol
IL147640A0 (en) * 2000-06-01 2002-08-14 Watson Pharmaceuticals Inc Transdermal delivery of lasofoxifene
EP1192945A3 (en) * 2000-09-21 2004-03-03 Pfizer Products Inc. Use of an estrogen agonist/antagonist for treating osteoarthritis
IL145876A0 (en) * 2000-10-17 2002-07-25 Pfizer Prod Inc Methods and kits for improving vascular health
ES2233570T3 (es) * 2000-11-30 2005-06-16 Pfizer Products Inc. Composicion que contiene agonistas/antagosnistas de estrogenos y testosterona para tratar un descenso en el nivel de la hormona testosterona.
PL367094A1 (en) * 2001-07-31 2005-02-21 Pfizer Products Inc. Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists/antagonists, estrogens and progestins
MY143244A (en) * 2002-11-26 2011-04-15 Smithkline Beecham Corp Calcilytic compounds
WO2011159769A2 (en) 2010-06-17 2011-12-22 Aragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
CA2849910A1 (en) 2011-09-30 2013-04-04 Perio Sciences, Llc Antioxidant compositions for treatment of inflammation or oxidative damage
CN103142644B (zh) * 2013-03-21 2014-07-23 青岛正大海尔制药有限公司 骨化三醇和氟化钠的混悬颗粒及其制备方法
WO2018071440A1 (en) 2016-10-11 2018-04-19 Duke University Treatment of breast cancer
CN117771239A (zh) 2018-04-10 2024-03-29 杜克大学 乳腺癌的拉索昔芬治疗
CN112384634B (zh) * 2018-04-24 2024-04-16 深圳华大生命科学研究院 骨质疏松生物标志物及其用途
CN110412289B (zh) * 2019-07-25 2022-08-02 北京美迪阿姆科技发展有限公司 抑制性t细胞及筛选方法和抑制自身免疫反应中的应用

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3274213A (en) 1961-09-05 1966-09-20 Upjohn Co Alkoxy-substituted 2-phenyl-1-(tertiary-aminoalkoxy)phenyl-3, 4-dihydronaphthalenes
US3234090A (en) 1962-09-10 1966-02-08 Ciba Geigy Corp Pharmaceutical compositions comprising saturated basic ethers
BE637389A (no) 1962-09-13
US3522319A (en) 1964-01-23 1970-07-28 Ciba Geigy Corp Phenol substituted tetrahydronaphthalenes useful as estrogenics
US3822287A (en) 1969-04-17 1974-07-02 Rexall Drug Chemical Process for preparation of substituted 3,4-(diphenyl)chromans
US3927197A (en) 1974-04-19 1975-12-16 Pfizer Tertiary alcohol stabilized E-series prostaglandins
US3932389A (en) 1974-12-11 1976-01-13 Pfizer Inc. 2-Descarboxy-2-(tetrazol-5-yl)-11-desoxy-15-substituted-.omega.-pentanorprostaglandins
US3982016A (en) 1975-08-06 1976-09-21 Pfizer Inc. Bone deposition by 16-aryl-13,14-dihydro-PGE2 p-biphenyl esters
US4000309A (en) 1975-08-06 1976-12-28 Pfizer Inc. Bone deposition by 16-aryl-13,14-dihydro-PGE2 p-biphenyl esters
US4018892A (en) 1975-08-06 1977-04-19 Pfizer Inc. Bone deposition by 16-aryl-13,14-dihydro-PGE2 p-biphenyl esters
US4133814A (en) 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4132847A (en) 1977-07-22 1979-01-02 Pfizer Inc. 4-Pyrone prostaglandin antagonists
EP0002097B1 (en) 1977-08-22 1981-08-05 Imperial Chemical Industries Plc Triphenylalkene derivatives, process for their preparation and pharmaceutical compositions containing them
US4097601A (en) 1977-08-26 1978-06-27 Pfizer Inc. Bone deposition by 2-descarboxy-2-(tetrazol-5-yl)-11-dexosy-16-aryl prostaglandins
US4171331A (en) 1978-06-05 1979-10-16 Miles Laboratories, Inc. 1 And 2-substituted analogues of certain prostaglandins
US4219483A (en) 1978-09-11 1980-08-26 Pfizer Inc. 4-Pyrone prostaglandin antagonists
DE3046719C2 (de) 1980-12-11 1983-02-17 Klinge Pharma GmbH, 8000 München 1,1,2-Triphenyl-but-1-en-Derivate, Verfahren zu ihrer Herstellung und Arzneimittel
US4418068A (en) 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4621100A (en) 1981-09-25 1986-11-04 The Upjohn Company Treatment of osteoporosis with prostaglandins
GB2126576B (en) 1982-06-25 1985-06-19 Farmos Group Limited Alkane and alkene derivatives
US4904478A (en) 1983-08-11 1990-02-27 Mission Pharmacal Company Slow-release sodium fluoride tablet and method for treatment of osteoporosis
DE3583887D1 (de) 1984-04-30 1991-10-02 Procter & Gamble Ausruestung fuer die behandlung der osteoporose.
US4729999A (en) * 1984-10-12 1988-03-08 Bcm Technologies Antiestrogen therapy for symptoms of estrogen deficiency
GB2196003A (en) 1986-09-11 1988-04-20 Nat Res Dev Iodo-and bromo-tamoxifen derivatives
US5216183A (en) 1988-04-19 1993-06-01 Teijin Limited Cyclopentanone/cyclopentenone derivative
EP0559751B1 (en) 1990-11-26 1997-03-26 RECKER, Robert R. Treatment for osteoporosis using growth hormone release factor (grf) in combination with parathyroid hormone (pth)
JPH04312526A (ja) * 1991-04-09 1992-11-04 Fujisawa Pharmaceut Co Ltd 骨疾患治療剤
US5118667A (en) 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
US5180720A (en) * 1991-05-03 1993-01-19 G. D. Searle & Co. 2- and 3-alkoxy or hydroxy-8-substituted-dibenz[b,f]-[1,4]oxazepine-10(11H)-carboxylic acid, substituted hydrazides and methods for treating pain
US5409911A (en) 1992-09-11 1995-04-25 Merck & Co., Inc. Prostaglandin analog for treating osteoporosis
WO1994013696A1 (en) 1992-12-11 1994-06-23 Merck & Co., Inc. Spiro piperidines and homologs which promote release of growth hormone
US5536716A (en) 1992-12-11 1996-07-16 Merck & Co., Inc. Spiro piperidines and homologs which promote release of growth hormone
TW383306B (en) 1992-12-22 2000-03-01 Lilly Co Eli New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol
TW303299B (no) * 1993-07-22 1997-04-21 Lilly Co Eli
PL314003A1 (en) * 1993-10-19 1996-08-05 Merck & Co Inc Combination of bisulphonates and substances enhancing secretion of growth hormone
HUT74733A (en) 1993-11-09 1997-02-28 Merck & Co Inc Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone
US5492916A (en) 1993-12-23 1996-02-20 Merck & Co., Inc. Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
JPH09505601A (ja) 1993-11-24 1997-06-03 メルク エンド カンパニー インコーポレーテッド インドリル基含有化合物類および成長ホルモン放出を促進するためのそれらの使用
US5441966A (en) 1993-12-21 1995-08-15 Eli Lilly And Company Methods of inhibiting Turner's syndrome
WO1995034311A1 (en) 1994-06-13 1995-12-21 Merck & Co., Inc. Piperazine compounds promote release of growth hormone
EP0779813A4 (en) * 1994-09-09 1998-05-06 Procter & Gamble PHOSPHONATES AND PARATHORMONE AGAINST OSTEOPOROSIS
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
US5767124A (en) 1995-10-27 1998-06-16 Merck & Co., Inc. Polymorphic forms of a growth hormone secretagogue
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
IL120270A0 (en) 1996-02-28 1997-06-10 Pfizer Combination therapy to treat osteoporosis
HN1996000101A (es) 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
US6100301A (en) 1996-02-28 2000-08-08 Pfizer Inc Combination therapy to treat osteoporosis-polyphosphonates and estrogen agonists
PL188164B1 (pl) 1996-05-07 2004-12-31 Pfizer Trihydrat metanosulfonianu 5-{2-[4-1,2-benzizotiazol-3-ilo)-1-piperazynylo]etylo}-6-chloro-1,3-dihydro-2H-indol-2-onu i środek farmaceutyczny
TW491847B (en) 1996-05-07 2002-06-21 Pfizer Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
IL126983A0 (en) 1996-05-31 1999-09-22 Novo Nordisk As Growth hormone components and bone anti-resorptive agent in cyclic (coherence) treatment of osteoporosis
GB2324726A (en) 1997-05-01 1998-11-04 Merck & Co Inc Combination Therapy for the Treatment of Osteoporosis
UA53716C2 (uk) * 1997-06-25 2003-02-17 Пфайзер Продактс Інк. Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти)
BR9803596A (pt) 1997-09-23 2000-04-25 Pfizer Prod Inc Derivados do resorcinol.
PA8471201A1 (es) * 1998-06-16 2000-09-29 Pfizer Prod Inc Combinaciones terapeuticas que comprenden un modulador del receptor de estrogenos selectivo y hormona paratiroidea

Also Published As

Publication number Publication date
UA69372C2 (en) 2004-09-15
CA2247420C (en) 2011-02-15
JPH11504352A (ja) 1999-04-20
AR005987A1 (es) 1999-07-21
KR19990087337A (ko) 1999-12-27
ZA971719B (en) 1998-08-27
AP9700934A0 (en) 1997-04-30
PT883404E (pt) 2008-11-14
GT199700009A (es) 1998-07-10
US20010009920A1 (en) 2001-07-26
DZ2186A1 (fr) 2002-12-02
YU7797A (sh) 2000-10-30
CA2247420A1 (en) 1997-09-04
CL2004000119A1 (es) 2005-02-11
AU1039897A (en) 1997-09-16
DE69637651D1 (en) 2008-10-02
NO983936D0 (no) 1998-08-27
PL328831A1 (en) 1999-02-15
BR9612533A (pt) 1999-07-20
GT199700009AA (es) 1999-01-23
ATE405273T1 (de) 2008-09-15
NZ323456A (en) 2001-03-30
EP0883404B1 (en) 2008-08-20
IS4812A (is) 1998-07-28
UY24472A1 (es) 2000-09-29
PE20011302A1 (es) 2001-12-25
CN1515258A (zh) 2004-07-28
ID19886A (id) 1998-08-13
EP1932543A3 (en) 2012-01-04
AP2002002661A0 (en) 2002-12-31
EP1236475A2 (en) 2002-09-04
PE58998A1 (es) 1998-10-16
EP0883404A1 (en) 1998-12-16
HUP9904123A2 (hu) 2000-05-28
EP1932543A2 (en) 2008-06-18
NO323648B1 (no) 2007-06-18
OA10837A (en) 2001-08-13
IL154380A0 (en) 2003-09-17
CN1515317A (zh) 2004-07-28
AP975A (en) 2001-06-12
AR060853A2 (es) 2008-07-16
AP1179A (en) 2003-06-30
NO983936L (no) 1998-08-27
CN1242813C (zh) 2006-02-22
HRP970118A2 (en) 1998-04-30
US6323232B1 (en) 2001-11-27
PL187962B1 (pl) 2004-11-30
TNSN97040A1 (fr) 2005-03-15
CZ297452B6 (cs) 2006-12-13
CN1209064A (zh) 1999-02-24
IL125493A0 (en) 1999-03-12
JP2002308771A (ja) 2002-10-23
CZ271898A3 (cs) 1999-06-16
ES2312169T3 (es) 2009-02-16
BG64582B1 (bg) 2005-08-31
TW464496B (en) 2001-11-21
AP974A (en) 2001-06-12
EP1236475A3 (en) 2003-11-05
TR199801679T2 (xx) 2001-06-21
RU2190395C2 (ru) 2002-10-10
HK1018210A1 (en) 1999-12-17
PL187219B1 (pl) 2004-06-30
SI0883404T1 (sl) 2008-10-31
HUP9904123A3 (en) 2001-01-29
SK118398A3 (en) 2000-07-11
MA26420A1 (fr) 2004-12-20
CN1515254A (zh) 2004-07-28
DK0883404T3 (da) 2008-10-20
HN1996000101A (es) 1997-06-26
AU703285B2 (en) 1999-03-25
AP2000001962A0 (en) 2000-12-31
CO4761063A1 (es) 1999-04-27
US7255984B2 (en) 2007-08-14
IL154379A0 (en) 2003-09-17
BG102726A (en) 1999-04-30
CN1515316A (zh) 2004-07-28
WO1997031640A1 (en) 1997-09-04

Similar Documents

Publication Publication Date Title
NO20063853L (no) Kombinasjonsterapi for osteoporose
MY129189A (en) Prostaglandin agonists and their use to treat bone disorders
MY141384A (en) Prevention of loss and restoration of bone mass by certain prostaglandin agonists
TW366342B (en) The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
TR199901172T2 (xx) Yeni ikame edilmi� pirazol t�revleri.
ES2144192T3 (es) Nuevos derivados de 1-fenil-2-dimetil-amino-metil-ciclohexan-1-ol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
HUP9700603A1 (hu) Gyógyászati készítmény véralvadási zavarok kezelésére
HUP0000558A3 (en) Use of active d vitamin analogues for producing pharmaceutical composition for the treatment of prostatic diseases
NO865079L (no) Fremgangsmaate for fremstilling av stabiliserte humanvevplasminogenaktivatorpreparater.
DK279790A (da) Aromatiske steroid-5-alfa-reduktaseinhibitorer
NO862096L (no) Fremgangsmaate for fremstilling av farmasoeytiske preparater inneholdende vevsplasminogenaktivator.
WO1998058911A3 (en) Prostaglandin agonists
IL110943A (en) Compositions comprising an inhibitor of cholesterol synthesis for the treatment of skin disorders
ZA933598B (en) New pharmaceutical used of krill enyzmes
AU563650B2 (en) Pharmaceutical compositions of benzothiophene derivatives
NO972391D0 (no) 2-substituerte 1,2,5-tiadiazolidin-3-on 1,1-dioksider og preparater og metoder for anvendelse derav
HUP0004544A2 (hu) Angiotenzin-átalakító enzim inhibitora és diuretikum kombinációjának alkalmazása mikrokeringési rendellenességek kezelésére szolgáló gyógyászati készítmény előállítására
NO921382D0 (no) Amidinofenylalaninderivater, samt fremstilling, anvendelse og preparater inneholdende forbindelsene
NO983465L (no) Farmasöytisk kombinasjonspreparater inneholdende LHRH-analoger og antiöstrogener for behandling av gynekologiske forstyrrelser
DE69120287D1 (en) Aminosulfonylharnstoff-acat-inhibitoren
MX9704034A (es) Derivados y composiciones de 1,1-dioxido de 2-arilcarboniloximetil-1,2,5-tiadiazolidin-3-ona substituido y metodo de uso.
NO863460D0 (no) Fremgangsmaate til fremstilling av 6-fenoksymetyl-4-hydroksy-tetrahydropyran-2-on, fremgangsmaate til deres fremstilling, og deres anvendelse som legemiddel, farmasoeytiske preparater og mellomprodukter.
IT1289154B1 (it) Derivati di isoflavone loro preparazione e loro impiego terapeutico
AU3406089A (en) Novel strobilurine derivatives, their preparation and their use
ATE75938T1 (de) Enantiomere des propafenons enthaltende therapeutische mittel.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application